Sign in Subscribe
Cancer research

Glycosylation Controls Immune Evasion in Non-Small Cell Lung Cancer

Strategic Insights

— 1 min read

New research at the University of Nebraska Medical Center has found that glycosylation, specifically tumor cell sialylation, regulates immune evasion and metastasis in non-small cell lung cancer. The study, funded by various organizations including the National Institutes of Health, identified a key role for the ST6GalNAc-I enzyme in sialylation of NECTIN2 and MUC5AC, leading to tumor immune evasion and angiogenesis.

Key Takeaways:

  • The study found that ST6GalNAc-I, a sialyltransferase, is overexpressed in aggressive-type non-small cell lung cancer (NSCLC) and regulates immune evasion and tumor angiogenesis.
  • Proteomic and biochemical analysis revealed that ST6GalNAc-I mediates NECTIN2 sialylation in NSCLC cells, leading to T cell dysfunction and reduced tumor cell killing.
  • Mice injected with ST6GalNAc-I-knockdown syngeneic cells showed reduced lung tumor incidence and Nectin2/Tigit-associated immunosuppression.
  • The study also found that administration of P-DMEA promotes NSCLC cell proliferation via MUC5AC and that MUC5AC interacted and colocalized with PRRC1 in the Golgi.
  • Mechanistically, ST6GalNAc-I/MUC5AC regulates VCAN-V1, a key factor in tumor matrix remodeling during angiogenesis and metastasis.

Statistics:

  • 135(10) edition of the Journal of Clinical Investigation published the research.
  • The study was funded by the National Institutes of Health (NIH), US Department of Veterans Affairs, NIH National Institute of General Medical Sciences (NIGMS), Nebraska Research Initiative, UNMC Vice Chancellor for Research Office, Fred & Pamela Buffett Cancer Center Support Grant, and R01 Investment Program.
  • The research identified a significant role for ST6GalNAc-I-mediated sialylation of NECTIN2/MUC5AC in immune evasion and tumor angiogenesis.
  • The study found that targeting this pathway may prevent NSCLC development and/or metastasis.

Sources:

  • NewsRx. New Non-Small Cell Lung Cancer Study Findings Have Been Reported by Researchers at University of Nebraska Medical Center (St6galnac-i Regulates Tumor Cell Sialylation Via Nectin2/muc5ac-mediated Immunosuppression and Angiogenesis In Non-small ...). Health & Medicine Week. July 25, 2025; p 2805.
  • St6galnac-i Regulates Tumor Cell Sialylation Via Nectin2/muc5ac-mediated Immunosuppression and Angiogenesis In Non-small Cell Lung Cancer. Journal of Clinical Investigation, 2025;135(10).
  • Amer Soc Clinical Investigation Inc, 2015 Manchester Rd, Ann Arbor, MI 48104, USA.

Read more